GlassScriptPhysician profile
Michael Edward Murray
NPI 1023002870
$3,883.12
in general payments reported to CMS, 2019-2025
14 companies · $734 in 2025
The $734 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $103 · 2021: $331 · 2022: $439 · 2023: $1,040 · 2024: $834 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $777.73 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $601.30 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $383.35 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $383.23 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $370.97 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $361.56 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $263.13 | 2019-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.96 | 2022-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $223.15 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $89.65 | 2021-2025 | Fanapt |
| Lundbeck LLC | $89.06 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $55.54 | 2019-2022 | |
| Axsome Therapeutics, INC. | $26.44 | 2023 | Auvelity |
| Allergan, INC. | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.